POPULARITY
Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Ruth Peetoom is voorzitter van de Nederlandse GGZ.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.
As the global pharmaceutical industry enters a period of profound transition, this episode of Corner Office Conversation examines what lies ahead. Hosts Vikas Dandekar and Teena Thacker talk to Stefan Oelrich, Head of the Pharmaceuticals Division at Bayer AG, about the forces reshaping drug discovery and access from trade tensions and shifting innovation hubs to the promise and uncertainty of cell and gene therapies. Oelrich reflects on Europe’s struggle to stay competitive as capital and talent flow increasingly toward the US and China, and argues that meaningful reform will require faster regulation, leaner bureaucracy, and quicker patient access. He also addresses the looming loss of exclusivity for blockbuster drugs and outlines how Bayer plans to offset revenue impact with a packed pipeline of new launches. India emerges as both an opportunity and a test case, offering scale and growth while raising tough questions on affordability and access. At its core, the conversation asks whether breakthrough science can move fast enough to serve patients without losing public trust.You can follow Vikas Dandekar on his social media: X and Linkedin and read his Newspaper Articles.You can follow Teena Thacker on his social media: X and Linkedin and read her Newspaper Articles.Listen to Corner Office Conversation: Corner Office Conversation with Knight Frank’s William Beardmore-Gray and Shishir Baijal, Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with Elizabeth Reid, Head of Search, Google and much more. Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.See omnystudio.com/listener for privacy information.
This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University's Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district's foundation. The guests talk about the life science assets, research strengths, and translational capabilities that define the district and explain why it is positioned to support biotechnology and advanced R&D companies. The conversation explores how the partnership between Prince William County, George Mason University, and the City of Manassas came together, outlining the distinct roles each plays in advancing a shared strategy. The episode also introduces the NISA program, detailing how it supports companies seeking a soft-landing pathway into the district, the types of organizations best suited for the program, and the facilities, talent, and collaborative resources participants can access both immediately and over time. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Jaehan Park is Founder and CEO of NAUGEN, a global innovation accelerator advancing novel technologies across life sciences and deep tech. With more than 25 years of experience in strategy and business development, he has led collaborations spanning cancer immunotherapy, vaccines, and biologics with global pharmaceutical companies and academic institutions. He leads the NISA Program in partnership with George Mason University and serves as a Mentor-in-Residence at KIC DC, supporting international startups entering U.S. markets. Amy Adams is Executive Director of George Mason University's Institute for Biohealth Innovation, where she advances biohealth research and innovation across more than 300 faculty and thousands of students. Her work focuses on partnerships, shared research infrastructure, and building hubs that connect academia with industry. She is co-leading the development of the Innovation District anchored at Mason's SciTech campus and serves on the boards of BioHealth Innovation and the Association of University Research Parks. Christina Winn leads the Prince William County Department of Economic Development, guiding investment, business growth, and redevelopment efforts across one of Virginia's largest counties. She is overseeing the development of a research-driven Innovation District in partnership with George Mason University and the City of Manassas, supported by a GO Virginia grant. Her career includes leading large-scale economic development initiatives that have driven significant capital investment, job creation, and national visibility for the region.
Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy. Discussion highlights: Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026 M&A is expected to remain precision-led and asset-focused, centered on differentiated science and key therapeutic areas Accelerating loss of exclusivity (2026–2029) is increasing reliance on external innovation Mid-sized deals have dominated, but clearer policy and better financing may enable larger strategic transactions As innovation globalizes, companies are sourcing assets more deliberately worldwide, with the US remaining a core life sciences hub Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Roel van den Akker, US Pharmaceutical & Life Sciences Deals Leader, PwCLinked Materials:https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Learn more about The 2030 Project: A Cornell Climate Initiative https://climate.cornell.edu/Cornell College of Engineering https://www.engineering.cornell.edu/Cornell College of Agriculture and Life Sciences https://cals.cornell.edu/As concerns about climate change intensify, researchers are exploring the potential for large-scale human intervention in the Earth's climate system – a set of strategies collectively known as geoengineering. Some of these strategies, called sunlight reflection methods, involve techniques like adding aerosols to the stratosphere to reflect a small portion of solar radiation back into space. Though still in the early stages of research, sunlight reflection and other geoengineering ideas raise complex scientific, ethical, and political questions.In this Keynote, three experts from Cornell University delve into what geoengineering is and what it isn't. Clarifying the science, the panel will separate fact from fiction and discuss why a cautious, transparent, and interdisciplinary approach is essential.This conversation is part of The 2030 Project: A Cornell Climate Initiative, administered by the Cornell Atkinson Center for Sustainability. Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.
Darkness Radio Presents: Reincarnation, NDE, AI & Life Sciences and Forbidden Masonry with Historian/Professor/Presenter/Archaeologist/ Podcaster/ Author, Dr. Heather Lynn! On Today's Darkness Radio, while traveling on the road, Dr. Heather Lynn graciously stops by for an intriguing chat about everything from reincarnation and the death process, to AI and life sciences, to favorite holiday traditions and their true roots, to a forbidden branch of Masonry that she is currently doing research on! WARNING: This program moves a mile a minute! and we like it that way! Find out more about Dr. Lynn at her website: https://www.drheatherlynn.com/ Wanna see those pictures of the Boars Head ceremony that Dr. Lynn was talking about? Head over here: https://drheatherlynn.substack.com/ Check out Dr. Lynn's podcast: https://www.drheatherlynn.com/the-midnight-academy Get Dr. Lynn's Book , "Annunaki Revelation...": https://bit.ly/4j16hbL Check out Jessica Freeburg's website and get tickets to her events here: https://jessicafreeburg.com/upcoming-events/ There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store! https://www.darknessradioshow.com/store/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page: https://www.youtube.com/@DRTimDennis #paranormal #supernatural #paranormalpodcasts #darknessradio #timdennis #drheatherlynn #historian #archaeologist #ancientaliens #coasttocoast #ghosts #spirits #hauntings #baphomet #annunaki #annunakirevelation #reincarnation #neardeathexperience #artificialintelligence #AI #freemasons #paranormalinvestigation #Psychics #Aliens #ancientegypt #pyramids #knightstemplar #UFO #UAP #Extraterrestrials #Alienspaceships #holidaytraditions
Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Today's guest is Robert Wenier, Global Head of Cloud and Infrastructure at AstraZeneca. Robert leads enterprise cloud, infrastructure, and platform strategy across a highly regulated, data-intensive global organization. Robert joins Emerj CEO and Head of Research Daniel Faggella to discuss how enterprise data and AI architectures are shifting from service-oriented and microservice models toward emerging agentic architectures that prioritize end-to-end business outcomes over stepwise technical execution. The conversation explores why AI is moving from a supporting role to a direct driver of competitive advantage, and how this changes expectations for infrastructure, data strategy, and leadership ownership. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show! Watch Daniel and Robert's conversation on our new YouTube Channel: youtube.com/@EmerjAIResearch.
About Mary Varghese Presti:Mary Varghese Presti is a transformational healthcare leader with over two decades of experience spanning clinical care, federal reform, biopharma, and health technology. As Corporate Vice President of Microsoft Health & Life Sciences, she drives growth in complex environments by creating clear strategy, aligning organizations, and operationalizing execution with discipline. Her prior roles include leading Nuance's Dragon Medical business, overseeing IBM Watson Health's Life Sciences portfolio, incubating new ventures at athenahealth, and driving digital-health transformation at Pfizer. She began her career as a pediatric nurse at Johns Hopkins and later helped shape national health IT and payment reforms at Booz Allen. Known for navigating complexity with optimism and rigor, she consistently turns ambiguity into strategy and strategy into measurable results.Things You'll Learn:AI in healthcare is evolving from simple assistants to agentic services that can independently execute predictable workflows, allowing clinicians to regain time and focus. This shift enables a hybrid workforce where human and digital colleagues work side by side.Dragon Copilot for nurses was designed specifically to support the way nurses document care, capturing structured inputs such as vitals, intake/output, and observations through natural speech. By reducing EHR time and ambiently recording bedside interactions, it helps turn “caring out loud” into complete documentation.Nurses spend more than a quarter of their 12-hour shifts documenting in the EHR, often feeling emotionally torn between screens and patients. AI that listens in the background can significantly reduce this burden while allowing for more presence at the bedside.New tools are starting to expose the “invisible work” nurses perform, from constant micro-assessments to coordination with ancillary departments. Making this work visible is a critical step toward properly valuing nursing labor and improving workforce planning.Real-world use cases, such as AI agents assembling data for tumor boards at academic centers, show that agentic workflows can compress decision timelines from weeks to days. These same principles can be extended to many clinical and non-clinical tasks, accelerating care while preserving clinician judgment.Resources:Connect with and follow Mary Varghese Presti on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft and Life Sciences website.Listen to Mary's previous interview on our podcast here.Watch Mary's keynote presentation at the HLTH conference here.
Darkness Radio Presents: Reincarnation, NDE, AI & Life Sciences and Forbidden Masonry with Historian/Professor/Presenter/Archaeologist/ Podcaster/ Author, Dr. Heather Lynn! On Today's Darkness Radio, while traveling on the road, Dr. Heather Lynn graciously stops by for an intriguing chat about everything from reincarnation and the death process, to AI and life sciences, to favorite holiday traditions and their true roots, to a forbidden branch of Masonry that she is currently doing research on! WARNING: This program moves a mile a minute! and we like it that way! Find out more about Dr. Lynn at her website: https://www.drheatherlynn.com/ Wanna see those pictures of the Boars Head ceremony that Dr. Lynn was talking about? Head over here: https://drheatherlynn.substack.com/ Check out Dr. Lynn's podcast: https://www.drheatherlynn.com/the-midnight-academy Get Dr. Lynn's Book , "Annunaki Revelation...": https://bit.ly/4j16hbL Check out Jessica Freeburg's website and get tickets to her events here: https://jessicafreeburg.com/upcoming-events/ There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store! https://www.darknessradioshow.com/store/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page: https://www.youtube.com/@DRTimDennis #paranormal #supernatural #paranormalpodcasts #darknessradio #timdennis #drheatherlynn #historian #archaeologist #ancientaliens #coasttocoast #ghosts #spirits #hauntings #baphomet #annunaki #annunakirevelation #reincarnation #neardeathexperience #artificialintelligence #AI #freemasons #paranormalinvestigation #Psychics #Aliens #ancientegypt #pyramids #knightstemplar #UFO #UAP #Extraterrestrials #Alienspaceships #holidaytraditions
In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials. The conversation touches upon how large language models (or LLMs) can be gotten into production in regulated spaces – and why generic models won't cut it in this domain – as well as the role of real-world data in quantifying and reducing patient burden. You can listen to episode 233 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
In this episode of Tiny Show and Tell Us, we read an email from “baby sis” aka Binky aka Sam's younger sister Caroline who writes in about an alarming pregnancy test that predates today's at-home tests. Then we talk about a fascinating study that found a dead salmon showed brain activity in an MRI machine. Spoiler: It wasn't actually alive, scientists just really needed to rethink MRI analysis. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together dynamic female leaders to discuss the transformative role of artificial intelligence in life sciences. It is also a call to action: to ensure women are not only present, but pivotal in shaping the future of AI in healthcare. In a new pharmaphorum podcast focused on the important and timely subject of women in AI, web editor Nicole Raleigh spoke with: Kate Eversole, event director at Pharma Brands; Celine Parmentier, EVP, head of global med comms at Real Chemistry; and Emma Slade, head of applied AI at Tangram Therapeutics. The guests discuss their own work with AI, the risk of training AI models predominantly on male data, and how, within life sciences, women are already shaping, challenging, and advocating for AI. The conversation also touches upon the possible next greatest impacts of AI in the sector, and the need to keep the ‘human in the loop', as well as the possible negative impacts if AI is relied upon too much. You can listen to episode 232 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from. Resources mentioned within the conversation are as below: Kotek, H., Dockum, R., & Sun, C. (2023). Gender Bias and Stereotypes in Large Language Models. arXiv:2304.02485. UN Women & UNESCO (2020). I'd Blush If I Could: Closing Gender Divides in Digital Skills Through Education. Tatman, R. (2017). Gender and dialect bias in YouTube's automatic captions. Criado-Perez, C. (2019). Invisible Women: Data Bias in a World Designed for Men. King, M. (2020). The Fix: Overcome the Invisible Barriers That Are Holding Women Back at Work. You can register to be a part of the women in AI community here: https://www.pharmabrands.ca/womeninai Information on the survey being run by Dr Michelle Penelope King, on AI and workplace motivation, can be found here: https://lnkd.in/eCg87_7w
On this episode of Radio Physics, summer intern Alice Lebedev-Migdal interviews physicist Ned Wingreen.Ned Wingreen is the Howard A. Prior Professor of the Life Sciences at Princeton University. He is a member of the Department of Molecular Biology and Associate Director of the Lewis-Sigler Institute for Integrative Genomics, where he is Director of Graduate Studies of the QCB Graduate Program. He is also Associate Director of the Princeton Center for Theoretical Science, and associated faculty in the Department of Physics. Ned received his Ph.D. in theoretical condensed matter physics from Cornell University in 1989. He did his postdoc in mesoscopic physics at MIT before moving, in 1991, to the NEC Research Institute in Princeton. At NEC, he continued to work in mesoscopic physics, but also started research in biophysics which grew into a general interest in problems at the interface of physics and biology. Ned joined Princeton University in 2004. Ned's current research focuses on modeling of bacteria, bacterial communities, phages, and other microorganisms, as well as studies of intracellular phase separation, and topics in immunology. He is a fellow of the American Physical Society and the American Association for the Advancement of Science. Listen to Radio Physics on KDNK.org every third Wednesday at 4:30pm.
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company's Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD). This achievement follows the company's December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer's disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer's treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer's disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer's disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation
Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This is EngineeringPro, where we talk to engineering professionals across the world about their experiences, insights into their industries, and learn more about how the engineering world works. Today's guest is Rodney, an engineer with over 20 years of experience in the oil and gas and power industries. He's currently working as an ICSS engineer in France. We'll explore his career journey, how he left his home in The Philippines for new opportunities in Europe, and how he navigates balancing family life with embracing new career opportunities. NES Fircroft has over 90 years' combined experience of delivering workforce solutions to the global energy industry. We provide tailored staffing solutions, sourced from a global talent pool by a dedicated, discipline specific team of consultants. We are proud to be the world's leading engineering staffing provider spanning the Oil & Gas, Power & Renewables, Infrastructure, Life Sciences, Mining, Automotive and Chemicals sectors worldwide.
On this episode Justin records live at HLTH25 in Las Vegas.This week on the final HLTH25 episode, Justin talks to Rowland Illing, MD, Global Chief Medical Officer and Director at Healthcare and Life Sciences at Amazon Web Services (AWS), and Jonathan Bush, Founder & Chief Executive Officer at Zus Health.
Series FiveThis episode of 'The New Abnormal' podcast features Erik Korsvik Ostergaard, who is a futures-thinker and strategic foresight consultant. He uses futures-thinking to be curious about current and coming trends, and to turn them into strategies. He focuses on transformation and the future of work, leadership, and collaboration; with a particular focus on the Life Science and Healthcare domains.Erik is also the author of "The Responsive Leader", "Teal Dots in an Orange World", and the newly published "Anticipatory Leadership". He's also written articles for Thinkers50, Børsen, the Global Peter Drucker Forum, Fair Observer, India CSR, CEO World, Thrive - and others.In this interview, we discuss all of the above, and along the way, Erik also outlines some of the issues on which he lectured at the renowned Copenhagen Business School for over a decade.So…enjoy!
This episode features Olivier Godement, Head of Product for Business Products at OpenAI, discussing the current state and future of AI adoption in enterprises, with a particular focus on the recent releases of GPT 5.1 and Codex. The conversation explores how these models are achieving meaningful automation in specific domains like coding, customer support, and life sciences: where companies like Amgen are using AI to accelerate drug development timelines from months to weeks through automated regulatory documentation. Olivier reveals that while complete job automation remains challenging and requires substantial scaffolding, harnesses, and evaluation frameworks, certain use cases like coding are reaching a tipping point where engineers would "riot" if AI tools were taken away. The discussion covers the importance of cost reduction in unlocking new use cases, the emerging significance of reinforcement fine-tuning (RFT) for frontier customers, and OpenAI's philosophy of providing not just models but reference architectures and harnesses to maximize developer success. (0:00) Intro(1:46) Discussing GPT-5.1(2:57) Adoption and Impact of Codex(4:09) Scientific Community's Use of GPT-5.1(6:37) Challenges in AI Automation(8:19) AI in Life Sciences and Pharma(11:48) Enterprise AI Adoption and Ecosystem(16:04) Future of AI Models and Continuous Learning(24:20) Cost and Efficiency in AI Deployment(27:10) Reinforcement Learning and Enterprise Use Cases(31:17) Key Factors Influencing Model Choice(34:21) Challenges in Model Deployment and Adaptation(38:29) Voice Technology: The Next Frontier(41:08) The Rise of AI in Software Engineering(52:09) Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint
Not a fan of daylight savings? Beyond the depressingly early sunsets, that may be because it's messing with your circadian clock. In this episode of Tiny Matters, we ask, “How do organisms — from bacteria to sea anemones to humans — keep track of time?” We talk about circadian clocks and how both internal molecular changes and environmental cues called “zeitgebers,” which include things like light and food, synchronize biological rhythms and help all of us survive.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Send us a textLeslie Edgar grew up in a large family Kuna, Idaho, where her parents emphasized the importance of hard work and education. Back then, she probably never knew that her life would take her to multiple states only to return as the J.R. Simplot Endowed Dean of the College of Agricultural and Life Sciences at the University of Idaho. What a journey.In this podcast, Dean Edgar breaks down how a land-grant university works with students, farmers, 4-H, FFA, extension agencies, and a host of other agriculture groups. Her message is simple. The University of Idaho has an amazing network of resources and projects to further the future of farming and ranching and they are accessible to a diversity of people that need them.
On today's episode, we're changing course a little. Instead of interviewing a life science company leader, we're speaking to someone who empowers them and helps their companies to grow!Elizabeth Chabe is the CEO of High Touch Group, a marketing consultancy firm specializing in life science clients. Her science marketing playbook, The Giant's Ladder, is a #1 bestseller, and her work has been featured in The New York Times, Entrepreneur and CNBC, among others.inquiries@elizabethchabe.com Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez
In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Michael Silverstein, Managing Partner of Healthcare IT & Life Sciences, DRI and Kamal Jethwani, MD, Co-Founder, Decimal.health and VP, Digital Ventures, Moffitt Cancer Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
Meet Breanne Buehl, Head of Healthcare & Life Sciences at Broadcom. They discuss how private and hybrid cloud strategies are transforming healthcare's digital infrastructure. They explore thought leadership topics including: 1. AI + Genomics Infrastructure: balancing innovation with compliance and cost. 2. Reducing Clinician Burnout: tech as a force multiplier, not a friction point. 3. Health Equity by Design: enabling access through scalable infrastructure. 5. Digital Transformation in Life Sciences: from discovery to delivery. From managing sensitive patient data and ensuring regulatory compliance to integrating generative AI for predictive analytics and precision medicine, Buehl explains how healthcare organizations can securely harness data for improved outcomes. The conversation dives into the “cloud repatriation” trend—why hospitals are moving critical workloads from public to private environments—and the role of automation and platform design in combating burnout and inefficiency across IT and clinical operations. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies
In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices
In 1975 workers at Life Science Products, a small makeshift pesticide factory in Hopewell, Virginia, became ill after exposure to Kepone, the brand name for the pesticide chlordecone. They made the poison under contract for a much larger Hopewell company, Allied Chemical. Life Science workers had been breathing in the dust for more than a year. Ingestion of the chemical made their bodies seize and shake. News of ill workers eventually led to the discovery of widespread environmental contamination of the nearby James River and the landscape of the small, working-class city. Not only had Life Science dumped the chemical, but so had Allied when the company manufactured it in the 1960s and early 1970s. The resulting toxic impact was not only on the city of Hopewell but also on the faraway fields where Kepone was used as an insecticide.Aspects of this environmental tragedy are all too common: corporate avarice, ignorance, and regulatory failure combined with race and geography to determine toxicity and shape the response. But the Kepone story also contains some surprising medical, legal, and political moments amid the disaster. With Poison Powder: The Kepone Disaster in Virginia and Its Legacy (U Georgia Press, 2023) Gregory S. Wilson explores the conditions that put the Kepone factory and the workers there in the first place and the effects of the poison on the people and natural world long after 1975. Although the manufacture and use of Kepone is now banned by the Environmental Protection Agency, organochlorines have long half-lives, and these toxic compounds and their residues still remain in the environment. Matthew Powell is a doctoral student studying history at the University of Georgia. He focuses on the intersection of environmental and labor history, looking at how workers understand the natural world around them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-south
On March 20th, 1995, the Tokyo subway system was flooded with sarin nerve gas in a coordinated terrorist attack by the religious cult Aum Shinrikyō. Led by the charismatic new-age guru, Shoko Asahara, the well-funded and technologically ambitious Aum organization manufactured and deployed chemical weapons in an attempt to bring about the end of the world. In the chaos that followed, 13 people were killed, thousands were injured, and the international community shuddered at the possibility of future attacks by fringe political groups. SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic. Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40. Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6. Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787. “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62. Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED. Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times. Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo. 2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83. Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80. Learn more about your ad choices. Visit megaphone.fm/adchoices
This is the Engineering Culture Podcast, from the people behind InfoQ.com and the QCon conferences. In this podcast, Shane Hastie, Lead Editor for Culture & Methods, spoke to Satish Kothapalli about the transformative impact of AI and vibe coding in life sciences software development, the acceleration of drug development timelines, and the evolving roles of developers in an AI-augmented environment. Read a transcript of this interview: https://bit.ly/3M2E9ZH Subscribe to the Software Architects' Newsletter for your monthly guide to the essential news and experience from industry peers on emerging patterns and technologies: https://www.infoq.com/software-architects-newsletter Upcoming Events: QCon AI New York 2025 (December 16-17, 2025) https://ai.qconferences.com/ QCon London 2026 (March 16-19, 2026) QCon London equips senior engineers, architects, and technical leaders with trusted, practical insights to lead the change in software development. Get real-world solutions and leadership strategies from senior software practitioners defining current trends and solving today's toughest software challenges. https://qconlondon.com/ QCon AI Boston 2026 (June 1-2, 2026) Learn how real teams are accelerating the entire software lifecycle with AI. https://boston.qcon.ai The InfoQ Podcasts: Weekly inspiration to drive innovation and build great teams from senior software leaders. Listen to all our podcasts and read interview transcripts: - The InfoQ Podcast https://www.infoq.com/podcasts/ - Engineering Culture Podcast by InfoQ https://www.infoq.com/podcasts/#engineering_culture - Generally AI: https://www.infoq.com/generally-ai-podcast/ Follow InfoQ: - Mastodon: https://techhub.social/@infoq - X: https://x.com/InfoQ?from=@ - LinkedIn: https://www.linkedin.com/company/infoq/ - Facebook: https://www.facebook.com/InfoQdotcom# - Instagram: https://www.instagram.com/infoqdotcom/?hl=en - Youtube: https://www.youtube.com/infoq - Bluesky: https://bsky.app/profile/infoq.com Write for InfoQ: Learn and share the changes and innovations in professional software development. - Join a community of experts. - Increase your visibility. - Grow your career. https://www.infoq.com/write-for-infoq
Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Welcome to Health-e Law, Sheppard Mullin's podcast exploring the fascinating health tech topics and trends of the day. In this episode, Michael Orlando welcomes Amy Dilcher and Chi Huynh, co-chairs of Sheppard Mullin's Women in Healthcare Leadership Collaborative (WHLC), to discuss key takeaways from the 2025 WHLC Leadership Summit. What We Discussed in this Episode: What is WHLC, and what is its mission? What is the purpose of the annual leadership summit? What was the theme for 2025? What topics were discussed during this year's summit panels? What were the key takeaways regarding healthcare transactions, AI, reimbursement and regulatory changes, and telehealth? Looking ahead to 2026, what's on WHLC's agenda? How can the annual summit help advance women in healthcare leadership? What do you see as the key drivers that help support women in leadership? How does the WHLC summit encourage collaboration? What is Legal Bridge Services, and what drove its creation? About Amy Dilcher Amy Dilcher is a partner in the Corporate Practice Group in Sheppard Mullin's Washington, D.C. office and Co-Chair of WHLC. With more than 25 years in the healthcare industry and a prior career as an oncology nurse, Amy's dual understanding of the clinical and legal aspects of healthcare enables her to deliver practical, tailored solutions that balance business goals with regulatory compliance. Amy advises hospitals, health systems, and private equity–backed organizations on strategic affiliations, hospital and physician transactions, regulatory compliance, and operational risk. Her background as Chief Legal Officer and General Counsel enables her to offer practical guidance that aligns legal strategy with business and clinical priorities. Her practice includes structuring and negotiating complex healthcare transactions, developing compliance programs, and supporting post-transaction integration. She also provides ongoing counsel to leadership teams navigating regulatory and operational challenges. Amy is certified as a Yellow Belt in Legal Process Improvement and Project Management through Legal Lean Sigma, and she assists clients in strengthening legal operations, improving workflow efficiency, and enhancing organizational performance. About Chi Huynh Chi Huynh is a partner in the Corporate Practice Group in Sheppard Mullin's Century City office and Co-Chair of WHLC. Her practice focuses on healthcare transactions, compliance, mergers and acquisitions, and corporate governance. Chi represents physician groups, independent physician associations, hospitals and affiliated foundations, nonprofit health organizations, pharmacies, and other healthcare entities in mergers and acquisitions, operational matters, contracting, and general corporate counsel work. She also handles healthcare regulatory issues involving information privacy, the corporate practice of medicine, anti-kickback rules, and Stark Law considerations. She also advises public and private companies, private equity firms, and strategic investors on mergers and acquisitions, joint ventures, investment structures, and corporate governance. Her work spans a range of industries, including semiconductor, food and beverage, specialty manufacturing, entertainment, energy, and renewable energy. Before joining Sheppard Mullin, Chi served as Associate General Counsel at IPC Healthcare, Inc., where she led a team responsible for negotiating, documenting, and closing more than 35 acquisitions across multiple states. About Michael Orlando Michael Orlando is a corporate and intellectual property transactions attorney in Sheppard Mullin's San Diego (Del Mar) office, where he leads the firm's Technology Transactions Team and is a member of the Life Sciences and Healthcare teams. Michael advises technology companies on the development, commercialization, and procurement of their products. His expertise covers a broad spectrum of transactions, including licensing, outsourcing, joint ventures, mergers and acquisitions, collaborations, and strategic partnerships. By integrating corporate and intellectual property law, Michael structures deals that align his clients' legal, technical, and business objectives. His practice serves a diverse range of industries—from biotechnology and digital health to aerospace and automotive technologies, with a particular focus on electric, autonomous, and connected vehicle systems. He represents a wide array of clients, from early-stage startups to Fortune 500 companies. Before entering private practice, Michael founded a software-as-a-service company and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements. Contact Info Amy Dilcher Chi Huynh Michael Orlando Resources Women in Leadership Healthcare Collaborative (WHLC) Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.
In this episode of Tiny Show and Tell Us, we read an email from a listener who, as a kid, shared a fun fact with her classroom: polar bears have black skin. Her teacher not only told her she was wrong but embarrassed her in front of the other students. Well, it's time to set the record straight. Polar bears do, in fact, have black skin and we do, in fact, love a grudge and are so glad to provide vindication. Then we talk about the hidden world of insect vibrational communication.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Oral Arguments for the Court of Appeals for the Federal Circuit
Life Science Logistics, LLC v. United States
Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Introduction: In this episode, host Sandy Vance sits down with Joerg Schwarz, Senior Director of Industry Strategy & Solutions for Healthcare Interoperability at Infor, and Adam Luff, a healthcare technology executive and VP of Solution Consulting at Infor. Together, they take a fascinating look at the real-world state of healthcare data. Together, they unpack what AI is actually doing for the industry, why pulling meaningful information from existing systems is so challenging, and how proprietary schemas and non-queryable databases keep organizations stuck with costly “zombie systems.” They explore the promise of using AI to finally unlock that trapped data, along with the critical measures needed to ensure accuracy, quality, and transparency as new technologies evolve. Make sure to check out this episode if you've ever wondered what's behind the “black box” of healthcare data.In this episode, they talk about:What AI does for the healthcare industryThe challenges that come with extracting dataWhy the data in current databases isn't searchable and queryableProprietary schemas Unable to pull one data table at a timeUsing AI to extract data from zombie systems The time and money it takes to keep zombie systems aliveMeasures with new tech that need to be taken to ensure accuracy and qualityTransparency and rejecting the “black box” approachA Little About Joerg and Adam:As a trusted and highly skilled Global Business Strategy Executive and seasoned thought leader in the Healthcare IT domain, Joerg keeps an acute focus on the customer while leading teams, building strategic partnerships, and delivering solutions with measurable outcome improvements. His knowledge runs wide and deep with a 360-degree vantage point through the lenses of Technology, Sales, Marketing, and Academia. He combines the realities of leading key stakeholders and teams through innovation with respect to Healthcare IT and Life Sciences throughout his distinguished career. Joerg is highly motivated towards the evolution of connected managed care, population health, and clinical analytics. Communicating complexity is a signature quality Joerg possesses in service to delivering mutual benefit "win-win-win's" by successfully navigating complex problems, accelerating brand and product growth, and being a key contributor in go-to-market decisions.Adam Luff is a healthcare technology executive and VP of Solution Consulting at Infor. With his 25 years in the Healthcare Technology industry, Adam focuses on operational efficiency that leads to providers getting paid faster and simpler.
This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Innovation is moving faster than the law, and investors are racing to keep up. In this episode, Brian Bewley, a partner in the Life Sciences and Health Industry group at Reed Smith, discusses how rapid technological advancements are reshaping healthcare and the life sciences faster than current regulations can keep pace. He explains how shifting federal policies, tariff disruptions, and turnover at key agencies, such as the FDA and HHS, have created uncertainty for investors. Brian also discusses how state-level laws are making it harder for private equity to fund healthcare innovation, and why that could slow progress. Still, he sees growing optimism as investors engage policymakers and prepare for a stronger market in 2026. Tune in to learn how legal, regulatory, and investment forces are converging to shape the future of healthcare innovation! Resources Connect with and follow Brian Bewley on LinkedIn, or reach out via email. Follow Reed Smith LLP on LinkedIn and visit their website.
Season 4, Episode 12: Jack Stone and Alex Gornik sit down with Jon Schultz, Co-Founder and Managing Principal of Onyx Equities, one of the Northeast's most active private real estate firms. Schultz—known for turning around complex office, industrial, and retail assets—shares how Onyx repositions properties, adapts across cycles, and captures value in a rapidly evolving market. From life sciences and medical office to AI-driven data centers, he breaks down the trends reshaping the tri-state region, the lessons learned from decades of leadership, and why success now depends on being “customer-obsessed. TOPICS 00:00 – Introduction 02:10 – Early Career and Founding Onyx Equities 06:15 – Navigating Market Cycles and Value Creation 09:30 – Office Market Shifts and Tenant Demand 12:45 – Life Sciences and Medical Office Expansion 17:40 – Inside the Data Center Gold Rush 22:15 – Rates, Debt, and Opportunities Ahead 27:48 – Tri-State vs. Sun Belt Market Dynamics 34:05 – Leadership, Adaptability, and Lessons Learned 42:30 – Building a Brand Tenants Trust Shoutout to our sponsor, Lev. The AI-powered way to get real estate deals financed. For more episodes of No Cap by CRE Daily visit https://www.credaily.com/podcast/ Watch this episode on YouTube: https://www.youtube.com/@NoCapCREDaily About No Cap Podcast Commercial real estate is a $20 trillion industry and a force that shapes America's economic fabric and culture. No Cap by CRE Daily is the commercial real estate podcast that gives you an unfiltered ”No Cap” look into the industry's biggest trends and the money game behind them. Each week co-hosts Jack Stone and Alex Gornik break down the latest headlines with some of the most influential and entertaining figures in commercial real estate. About CRE Daily CRE Daily is a digital media company covering the business of commercial real estate. Our mission is to empower professionals with the knowledge they need to make smarter decisions and do more business. We do this through our flagship newsletter (CRE Daily) which is read by 65,000+ investors, developers, brokers, and business leaders across the country. Our smart brevity format combined with need-to-know trends has made us one of the fastest growing media brands in commercial real estate.
In today's episode, we chat with author Sam Kean about his new book Dinner with King Tut and learn how researchers and citizen scientists are recreating ancient recipes, tools, and technologies — from wound remedies with pennies to inventive pottery glazed in blood — and how experimental archaeology is changing our understanding of the past. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
過去一年，你有沒有也覺得自己被各種 AI 相關內容鋪天蓋地地轟炸？從遇到疑難雜症請它幫忙搜尋、整理資料、處理公事，到純粹當成娛樂、請它生成各種有趣圖片，AI 的應用就像當年的網路搜尋一樣，幾乎無所不在地滲入我們的生活。 這集的三腳貓實驗室裡，在日常工作與生活中頻繁使用 AI 的「一般用戶」浩文和天豪，以及在生醫產業中運用 AI 參與藥物研究，並時刻關注AI前沿發展進程的「高階玩家」Mike，一起來聊聊現在 AI 在生醫學者日常中的各種使用場景，還有目前在大眾應用層面上的發展與限制。 我們或許已經習慣打開 AI 工具的網頁，在介面裡點選、輸入、獲得服務，就像多年前逐漸習慣使用 Google 一樣。但我們準備好迎接下一個階段了嗎？一個可以自己設計、客製化各種 Agent，自動幫你處理需求的時代？面對功能愈來愈強大的 AI 工具，你是否也開始擔心，身為「人」在科學研究中的角色，會不會很快被取代？歡迎你來聽聽這一集，和我們一起思考、一起面對這個正洶湧而來的新時代。 相關連結 如何使用AI工具提升科學研究生產力: Dr. Candice Chu's talk https://www.youtube.com/watch?v=CTTESpCK4yc https://www.nature.com/articles/d41586-024-03775-7 Chain of thought prompting: https://www.prompthub.us/blog/chain-of-thought-prompting-guide https://research.google/blog/accelerating-scientific-breakthroughs-with-an-ai-co-scientist/ 工作人員 內容製作：MIke、浩文、天豪 後製：天豪 文案：天豪 音樂：雯薇 封面：雯薇 上架：天豪 宣傳：Angel、雯薇 -- Hosting provided by SoundOn
On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Rasu Shrestha, MD MBA, Chief Innovation and Commercialization Officer, EVP at Advocate Health and Rowland Illing, MD. Global Chief Medical Officer and Director, Healthcare and Life Sciences at Amazon Web Services (AWS). To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
The Land of the Rising Sun, once a powerhouse in research and development, saw its share of global innovation slip following the 1990s. Now, Japan's leaders are seeking to reigniting its innovation culture. Sam Lim, executive director of EastGate Capital Management, explains. (11/2025)
Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode of Tiny Show and Tell Us, we talk about different ways of turning pennies all of the colors of the rainbow. Then we discuss an ongoing NASA mission to touch the sun.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Have you ever wondered why your dog takes such a long time to sniff a patch of grass? Or why flies buzz around so sporadically? It’s because most of what a creature actually senses is invisible to us. They perceive their world as differently as we perceive our own. Pulitzer Prize winning science writer Ed Yong wrote a book about this called An Immense World: How Animal Senses Reveal the Hidden Realms Around Us. Join me for a fun conversation with Ed about the astonishing ways animals sense the world around us. From birds that navigate the open ocean by smell, to penguins that sense vibrations underground. By learning how animals perceive their world, it just might change the way we perceive them, and make us look at our own world a little differently. Check out our episode about AI and Animal Communication: Digital Dr. Dolittle: decoding animal conversations with artificial intelligence. Enjoy BONUS CONTENT and help us continue to create this special immersive storytelling by joining THE WILD Patreon community at www.patreon.com/chrismorganwildlife and you can donate to KUOW at kuow.org/donate/thewild. Thank you. Follow us on Instagram @chrismorganwildlife and @thewildpod for more adventures and behind the scenes action! THE WILD is a production of KUOW in Seattle in partnership with Chris Morgan Wildlife and Wildlife Media. It is produced by Matt Martin and Lucy Soucek, and edited by Jim Gates. It is hosted, produced and written by Chris Morgan. Fact checking by Apryle Craig. Our theme music is by Michael Parker.See omnystudio.com/listener for privacy information.
© 2020-2025 Ivy Podcast Discovery LLC
